Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
    • IPOs
  • InderesTV
  • Forum
  • Discovery
  • Om os
    • Fulgte selskaber
    • Team
Analytikerkommentar

Aiforia launches new AI platform

Aiforia Technologies

Translation: Original published in Finnish on 12/18/2025 at 8:20 am EET.

Aiforia announced on Wednesday the launch of a new generation AI platform that utilizes Vision Transformer technology. The new technology promises to accelerate the development of AI models and improve their performance, supporting the expansion of the company's product portfolio. The news has no direct impact on our forecasts, but we view the increased efficiency in product development positively, as it partly mitigates risks related to the company's innovation capabilities after cost cuts and supports its long-term competitiveness.

The new Foundation Engine solution enhances model development

Aiforia announced on Wednesday that it is expanding its AI platform with a new solution called Foundation Engine, which is based on the Vision Transformer architecture. According to the company, the new solution combines so-called foundation models, pre-trained on extensive image datasets, with task-specific annotations made by pathologists. Aiforia highlights that the key benefits of the technology are the acceleration of AI model development and the improved generalizability of models to different image datasets. The new technology will be deployed in Aiforia's own product development and will also be integrated into the Aiforia Create development tool available to customers.

The company referred to the benefits of the expansion in its own product development earlier in the fall, so the launch does not come as a particular surprise or put pressure on forecast changes. In any case, the acceleration of model development supports the company's goals to improve its operational efficiency. Aiforia has recently focused on optimizing its cost structure and securing its path to profitability. In our view, more efficient product development through new technology mitigates the risks of cost savings to the company's innovation pace and supports the company's ability to maintain competitiveness in the long term. In addition to supporting the expansion of the product portfolio in the clinical segment, which is central to Aiforia's growth strategy, the technology also fundamentally strengthens Aiforia's product for its research customers who develop their own models on the Aiforia platform.

 

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Læs mere på virksomhedsside

Key Estimate Figures19.11.2025

202425e26e
Omsætning2,93,35,1
vækst-%18,9 %16,4 %55,0 %
EBIT (adj.)-12,2-10,9-8,6
EBIT-% (adj.)-427,8 %-328,4 %-167,6 %
EPS (adj.)-0,41-0,39-0,28
Udbytte0,000,000,00
Udbytte %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forumopdateringer

Bare flere og flere af disse, de bliver desværre bare monetariseret ret langsomt. Ventetiden føles lang, især når alle parter skal gennemgå ...
for 11 timer siden
af Opa
29
Referatet fra generalforsamlingen kan findes på Aiforias hjemmeside (investors/AGM2026) Det var tæt, 65 % stemte for, når der krævedes 2/3, ...
i går
af Puutaheinää
9
Interessant forklaring… Det sker åbenbart også i de finere kredse. Anyway, i den oprindelige indkaldelse til generalforsamlingen var dette aktieemissi...
i går
af Opa
6
Nu er der kommet en forklaring på blokeringen af emissionen på den ordinære generalforsamling: ”Den aktionær, der har anmodet om den ekstraordin...
i går
af Vino Pino
8
Der var også anelser om dette den 25. december Det er et ret nicheområde, nemlig forudsigelse af behandlingsresultater for metastatisk blærekr...
i går
af Vino Pino
13
Se nu der, det ramte plet! Vinket var denne finansiering, hvor et projekt af en Dana-Farber-forsker ramte lidt for præcist det, som Aiforias...
14.4.2026, 16.27
af Puutaheinää
19
aiforia.com Aiforia Announces Collaboration on Bladder Cancer Research with Renowned... Aiforia and Dana-Farber Cancer Institute partner to ...
14.4.2026, 16.18
af Salvelinus
16
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.